23037-58-3

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-Methoxyphenyl)butan-2-one is used as an intermediate in the synthesis of various pharmaceutical compounds. Its chemical structure allows for the creation of a range of medicinal products, contributing to the development of new drugs and therapies.
Used in Perfumery:
1-(3-Methoxyphenyl)butan-2-one is used as a fragrance ingredient in the perfumery industry. Its sweet, floral odor makes it a valuable component in creating complex and appealing scents for perfumes and other fragranced products.
Used in Food Industry:
In the food industry, 1-(3-Methoxyphenyl)butan-2-one is used as a flavoring agent. Its pleasant aroma and taste enhance the sensory experience of various food products, making it a sought-after additive in the culinary world.
Used in Chemical Synthesis:
1-(3-Methoxyphenyl)butan-2-one is also utilized in various chemical synthesis processes due to its reactive ketone group and aromatic ring. This makes it a valuable building block for creating a wide array of chemical products, from specialty chemicals to advanced materials.

Upstream product

• 925-90-6 ethylmagnesium bromide 
• 6834-42-0 3-methoxyphenylacetic acid chloride 
• 144828-84-2 N-methoxy-1′-(3-methoxyphenyl)-N-methylacetamide 
• 1798-09-0 m-methoxyphenylacetic acid 

Downstream Products

• 97968-21-3 2-Ethyl-6-methoxy-3-(3-methoxyphenyl)-indole 
• 97968-39-3 Acetic acid 3-(6-acetoxy-1,2-diethyl-1H-indol-3-yl)-phenyl ester 
• 97968-30-4 1,2-Diethyl-6-methoxy-3-(3-methoxy-phenyl)-1H-indole 

Relevant academic research and scientific papers

N-Phenyl-1,2,3,4-tetrahydroisoquinoline: An Alternative Scaffold for the Design of 17β-Hydroxysteroid Dehydrogenase 1 Inhibitors

17β-Hydroxysteroid dehydrogenases catalyse interconversion at the C17 position between oxidized and reduced forms of steroidal nuclear receptor ligands. The type 1 enzyme, expressed in malignant cells, catalyses reduction of the less-active estrone to estradiol, and inhibitors have therapeutic potential in estrogen-dependent diseases such as breast and ovarian cancers and in endometriosis. Synthetic decoration of the nonsteroidal N-phenyl-1,2,3,4-tetrahydroisoquinoline (THIQ) template was pursued by using Pomeranz-Fritsch-Bobbitt, Pictet-Spengler and Bischler-Napieralski approaches to explore the viability of this scaffold as a steroid mimic. Derivatives were evaluated biologically in vitro as type 1 enzyme inhibitors in a bacterial cell homogenate as source of recombinant protein. Structure-activity relationships are discussed. THIQs possessing a 6-hydroxy group, lipophilic substitutions at the 1- or 4-positions in combination with N-4′-chlorophenyl substitution were most favourable for activity. Of these, one compound had an IC50 of ca. 350 nM as a racemate, testifying to the applicability of this novel approach.

HELIX 12 DIRECTED STEROIDAL PHARMACEUTICAL PRODUCTS

Compounds having the structure or their salts: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Some of these compounds having tissue-specific antiandrogenic activity and tissue-specific androgenic activity can be used to treat or reduce the risk of developing diseases related to loss of androgenic stimulation. Combinations with other active pharmaceutical agents are also disclosed.